New biomedical strategies for HIV-1 prevention in women



Novel HIV-1 prevention strategies continue to be urgently needed. This article reviews the current state of biomedical prevention against HIV-1, focusing on recently completed and ongoing clinical trials of new prevention interventions, particularly those relevant to prevention of HIV-1 in women. Male circumcision, cervical barrier devices, suppressive therapy against herpes simplex virus type 2, treatment of vaginal infections and other vaginal health interventions, pre-exposure antiretroviral prophylaxis, and topical vaginal microbicides are discussed.

References and Recommended Reading

  1. 1.
    UNAIDS/WHO: 2007 AIDS Epidemic Update: December 2007. Available at Accessed May 15, 2008.
  2. 2.
    Mbulaiteye SM, Mahe C, Whitworth JA, et al.: Declining HIV-1 incidence and associated prevalence over 10 years in a rural population in south-west Uganda: a cohort study. Lancet 2002, 360:41–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen J: Did Merck’s failed HIV vaccine cause harm? Science 2007, 318:1048–1049.PubMedCrossRefGoogle Scholar
  4. 4.
    Gray RH, Wawer MJ, Brookmeyer R, et al.: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149–1153.PubMedCrossRefGoogle Scholar
  5. 5.
    Baeten JM, Overbaugh J: Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res 2003, 1:69–86.PubMedCrossRefGoogle Scholar
  6. 6.
    Royce RA, Sena A, Cates W Jr, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997, 336:1072–1078.PubMedCrossRefGoogle Scholar
  7. 7.
    Dunkle KL, Stephenson R, Karita E, et al.: New heterosexually transmitted HIV infections in married or cohabitating couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008, 371:2183–2191.PubMedCrossRefGoogle Scholar
  8. 8.
    Auvert B, Taljaard D, Lagarde E, et al.: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005, 2:e298.PubMedCrossRefGoogle Scholar
  9. 9.
    Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007, 369:657–666.PubMedCrossRefGoogle Scholar
  10. 10.
    Bailey RC, Moses S, Parker CB, et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007, 369:643–656.PubMedCrossRefGoogle Scholar
  11. 11.
    Mattson CL, Campbell RT, Bailey RC, et al.: Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS ONE 2008, 3:e2443.PubMedCrossRefGoogle Scholar
  12. 12.
    Weiss HA, Halperin D, Bailey RC, et al.: Male circumcision for HIV prevention: from evidence to action? AIDS 2008, 22:567–574.PubMedGoogle Scholar
  13. 13.
    Westercamp N, Bailey RC: Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review. AIDS Behav 2007, 11:341–355.PubMedCrossRefGoogle Scholar
  14. 14.
    Gray RH, Kiwanuka N, Quinn TC, et al.: Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 2000, 14:2371–2381.PubMedCrossRefGoogle Scholar
  15. 15.
    Wawer M, Kigozi G, Serwadda D, et al.: Trial of male circumcision in HIV+ men, Rakai, Uganda: effects in HIV+ men and in women partners [abstract 33LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.Google Scholar
  16. 16.
    Moench TR, Chipato T, Padian NS: Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 2001, 15:1595–1602.PubMedCrossRefGoogle Scholar
  17. 17.
    Padian NS, van der Straten A, Ramjee G, et al.: Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007, 370:251–261.PubMedCrossRefGoogle Scholar
  18. 18.
    Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004, 35:435–445.PubMedCrossRefGoogle Scholar
  19. 19.
    Freeman EE, Weiss HA, Glynn JR, et al.: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Baeten JM, McClelland RS, Corey L, et al.: Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004, 189:1466–1471.PubMedCrossRefGoogle Scholar
  21. 21.
    Freeman EE, Orroth KK, White RG, et al.: Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect. 2007, 83Suppl 1:i17–i24.PubMedCrossRefGoogle Scholar
  22. 22.
    Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560–1571.PubMedCrossRefGoogle Scholar
  23. 23.
    Celum C, Wald A, Hughes J, et al.: Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo-controlled trial. Lancet 2008, 371:2109–2119.PubMedCrossRefGoogle Scholar
  24. 24.
    Dunne E, Whitehead S, Sternberg M, et al.: The effect of suppressive acyclovir therapy on HIV cervicovaginal shedding in HIV-and HSV-2-infected women, Chiang Rai, Thailand [abstract 30]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.Google Scholar
  25. 25.
    Delany S, Mayaud P, Clayton T, et al.: Impact of HSV-2 suppressive therapy on genital and plasma HIV-1 RNA in HIV-1 and HSV-2-seropositive women not taking ART: a randomized, placebo-controlled trial in Johannesburg, South Africa [abstract 154LB]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.Google Scholar
  26. 26.
    Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790–799.PubMedCrossRefGoogle Scholar
  27. 27.
    Zuckerman RA, Lucchetti A, Whittington WL, et al.: Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007, 196:1500–1508.PubMedCrossRefGoogle Scholar
  28. 28.
    Baeten JM, Strick LB, Luccheti A, et al.: Herpes simplex virus suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial [abstract 676]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.Google Scholar
  29. 29.
    Røttingen J-A, Cameron DW, Garnett GP: A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001, 28:579–597.PubMedCrossRefGoogle Scholar
  30. 30.
    Taha TE, Kumwenda NI, Kafulafula G, et al.: Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and-infected women: a randomized clinical trial. PLoS Clin Trials 2007, 2:e10.PubMedCrossRefGoogle Scholar
  31. 31.
    McClelland RS, Richardson BA, Hassan WM, et al.: Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008, 197:1361–1368.PubMedCrossRefGoogle Scholar
  32. 32.
    Gray RH, Wawer MJ: Reassessing the hypothesis on STI control for HIV prevention. Lancet 2008, 371:2064–2065.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaul R, Kimani J, Nagelkerke NJ, et al.: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004, 291:2555–2562.PubMedCrossRefGoogle Scholar
  34. 34.
    Myer L, Kuhn L, Stein ZA, et al.: Intravaginal practices, bacterial vaginosis, and women’s susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005, 5:786–794.PubMedCrossRefGoogle Scholar
  35. 35.
    McClelland RS, Lavreys L, Hassan WM, et al.: Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. AIDS 2006, 20:269–273.PubMedCrossRefGoogle Scholar
  36. 36.
    Brotman RM, Ghanem KG, Klebanoff MA, et al.: The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. Am J Obstet Gynecol 2008, 198:628.e1–628.e7.CrossRefGoogle Scholar
  37. 37.
    Bunnell R, Ekwaru JP, Solberg P, et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006, 20:85–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Kumwenda NI, Hoover DR, Mofenson LM, et al.: Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008, 4:4.Google Scholar
  39. 39.
    Garcia-Lerma JG, Otten RA, Qari SH, et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008, 5:e28.PubMedCrossRefGoogle Scholar
  40. 40.
    Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27.PubMedCrossRefGoogle Scholar
  41. 41.
    AIDS Vaccine Advocacy Coalition: PrEP Watch. Available at Accessed June 30, 2008.
  42. 42.
    van de Wijgert JH, Shattock RJ: Vaginal microbicides: moving ahead after an unexpected setback. AIDS 2007, 21:2369–2376.PubMedGoogle Scholar
  43. 43.
    Ramjee G, Govinden R, Morar NS, Mbewu A: South Africa’s experience of the closure of the cellulose sulphate microbicide trial. PLoS Med 2007, 4:e235.PubMedCrossRefGoogle Scholar
  44. 44.
    Global HIV Prevention Working Group: Bringing HIV prevention to scale: an urgent global priority, June 2007. Available at Accessed June 30, 2008.
  45. 45.
    Kreiss J, Ngugi E, Holmes K, et al.: Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992, 268:477–482.PubMedCrossRefGoogle Scholar
  46. 46.
    Roddy RE, Zekeng L, Ryan KA, et al.: A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998, 339:504–510.PubMedCrossRefGoogle Scholar
  47. 47.
    Van Damme L, Ramjee G, Alary M, et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971–977.PubMedCrossRefGoogle Scholar
  48. 48.
    Peterson L, Nanda K, Opoku BK, et al.: SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007, 2:e1312.PubMedCrossRefGoogle Scholar
  49. 49.
    Feldblum PJ, Adeiga A, Bakare R, et al.: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008, 3:e1474.PubMedCrossRefGoogle Scholar
  50. 50.
    Population Council: Trial shows anti-HIV microbicide is safe, but does not prove it effective. Available at Accessed June 30, 2008.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Departments of Global Health and MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations